Skip to content

Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients

Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients: a Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04411381
Enrollment
136
Registered
2020-06-02
Start date
2020-05-25
Completion date
2023-12-31
Last updated
2023-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Telemedicine

Brief summary

To achieve World Health Organization 2030 goals of hepatitis C elimination it is mandatory to document after treatment sustained virological response (SVR). Currently, patients after completing treatment do not show up for SVR assessment. The main objective of this study is to evaluate the effectiveness of a telemedicine-based model of care associated with dried blood spot testing at home to assess hepatitis C sustained virological response after treatment compared to the traditional model of care.

Detailed description

This is a prospective, randomized study in which hepatitis C (VHC) infected patients will be randomized to two strategies for HCV care. All HCV infected patients will be evaluated in a first face-to-face consultation with the hepatologist for fibrosis evaluation and treatment prescription the same day. Patients will be invited to participate if they are: 1) 18 years or older 2) have contact telephone number 3) sing the informed consent 4) have not advanced fibrosis (F3) or cirrhosis (F4) 5) are not under surveillance by another specialist or drug addiction centre. Participants will be randomized into two strategies to assess sustained virological response (SVR) during follow-up: 1. The traditional model of care: one appointment for venipuncture for RNA testing to assess SVR (undetectable RNA 12 weeks after treatment cessation), and an appointment with the specialist for result communication. 2. Telemedicine-based model of care: The patient will be provided with a home kit to perform the dried blood spot (DBS) testing for HCV RNA at 12 weeks (SVR), and an appointment for teleconsultation and communicate the results. Demographic, clinical and laboratory data will be collected to evaluate the characteristics of included patients and to study predictive factors of adherence. A satisfaction questionnaire will be conducted to compare patients´ satisfaction with both health care models. The hypothesis of the study is that the adherence and SVR determination record will increase using the telemedicine-based model of care. For the present study, a 20% improvement in the adherence (SVR record) was hypothesized in the group of patients randomized to the telemedicine-based model of care compared to the traditional model of care. Taking into account power of 80%, alpha error of 5% and losses of 10% will require 68 patients per group.

Interventions

OTHERTelemedicine

Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination

Sponsors

University of La Laguna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * have contact telephone number * sing the informed consent

Exclusion criteria

* have advanced fibrosis (F3) or cirrhosis (F4) * are under surveillance by another specialist or drug addition center.

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of the two models of care12 monthsSVR record rate

Secondary

MeasureTime frameDescription
Acceptance of the intervention with a validated satisfaction questionnaire12 monthsGrade of patient satisfaction with telemedicine by a validated questionnaire

Countries

Spain

Contacts

Primary ContactManuel Hernández-Guerra, PhD
mhernand@ull.edu.es34922678559

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026